Post-therapy imaging of 225Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a gastric NET case report, the first whole-body and SPECT/CT images demonstrated high tumor uptake of 225Ac-DOTATATE.
“First whole-body and SPECT/CT images demonstrating high tumor uptake of 225Ac -DOTATATE.”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [160]
Cites
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M. M., Królicki, L., & Bruchertseifer, F. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180502104524 · Cited by 371 · see citing works
Ballal, S., Yadav, M. P., Bal, C., Sahoo, R. K., & Tripathi, M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04567-2 · Cited by 215 · see citing works
Navalkissoor, S., & Grossman, A. B. (2018) · Neuroendocrinology · doi:10.1159/000494760 · Cited by 99 · see citing works
Zhang, J., Kulkarni, H., & Baum, R. P. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002915 · Cited by 41 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68 · see citing works
Alan Selçuk, N., Demirci, E., Ocak, M., Toklu, T., Ergen, S., & Kabasakal, L. (2022) · Molecular Imaging and Radionuclide Therapy · doi:10.4274/mirt.galenos.2022.64497 · Cited by 7 · see citing works
Self-citation
- Authors
- Ocak, M., Toklu, T., Demirci, E., Selçuk, N., & Kabasakal, L.
- Affiliations
- Istanbul University (TR)
- Yeditepe University (TR)
- Corresponding author
- Kabasakal, Levent
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2020-03-02
- Volume
- 47
- Issue
- 11
- Pages
- 2711-2712
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W3009357674
- Cited by
- 33
- References
- 4
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 7 · 2023: 4 · 2022: 6 · 2021: 4 · 2020: 3
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- alpha therapy, neuroendocrine tumors, recurrent tumor, radionuclide therapy
- MeSH terms
- Humans, Neoplasm Recurrence, Local, Organometallic Compounds, Neuroendocrine Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
